INVO BioScience
INVO

$0.6918

0.92%

Market Cap: $2.7M

About: INVO Bioscience Inc operates a healthcare services fertility company. Assisted Reproductive Technology (ART) marketplace by making fertility care more accessible and inclusive to people. Its commercial strategy is focused on operating fertility-focused clinics, which includes the opening of dedicated INVO Centers offering the INVOcell and IVC procedure (with three centers in North America now operational) and the acquisition of US-based, profitable in vitro fertilization (IVF) clinics. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.

Employees: 30

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

9% more funds holding

Funds holding: 11 [Q1] → 12 (+1) [Q2]

1.41% less ownership

Funds ownership: 4.59% [Q1] → 3.18% (-1.41%) [Q2]

20% less capital invested

Capital invested by funds: $128K [Q1] → $103K (-$25.2K) [Q2]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INVO.

See Analyst Rankings

Financial journalist opinion

INVO Reports Record First Quarter 2024 Financial Results

SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update.

INVO Reports Record First Quarter 2024 Financial Results

Why Is Invo Bioscience (INVO) Stock Up 85% Today?

Invo Bioscience (NASDAQ: INVO ) stock is rocketing higher on Wednesday alongside its earnings report for the fourth quarter of 2023. The healthcare services fertility company reported a net loss of $2 million during the quarter.

Why Is Invo Bioscience (INVO) Stock Up 85% Today?

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

Abstract from 2023 American Society of Hematology (ASH) Meeting Data demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024 NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 AVENTURA, Fla. and SARASOTA, Fla.

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer (NK) cells for the treatment of cancer Partnership may be expanded to joint clinical development following successful completion of the initial research Combination therapy expected to improve response rate and address significant unmet medical need in hepatocellular carcinoma (HCC) NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 AVENTURA, Fla. and SARASOTA, Fla.

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

SARASOTA, Fla. , Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the Company received notice from The Nasdaq Capital Market, LLC ("Nasdaq"), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders' equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq.

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

See News Rankings